Expression of LMP-1, BCL-6, BCL-2, and hMSH2 in AIDS-Related and AIDS-Unrelated PCNSL
| Case . | HIV . | Diagnosis . | EBV* . | Immunohistochemistry . | ||||
|---|---|---|---|---|---|---|---|---|
| REAL . | WF . | LMP-1 (%) . | BCL-6 (%) . | BCL-2 (%) . | hMSH2 (%) . | |||
| 1 | + | DLCL | LNCCL | + | 0 | 50-75 | 0 | >75 |
| 2 | + | DLCL | LNCCL | + | 0 | 25-50 | 0 | >75 |
| 3 | + | DLCL | LNCCL | + | 0 | 50-75 | 0 | >75 |
| 4 | + | DLCL | LNCCL | + | 0 | 25-50 | 0 | 50-75 |
| 5 | + | DLCL | LNCCL | + | 0 | 50-75 | 0 | >75 |
| 6 | + | DLCL | LNCCL | + | 0 | 10-25 | 0 | 50-75 |
| 7 | + | DLCL | LNCCL | + | 0 | 10-25 | 0 | 10-25 |
| 8 | + | DLCL | IBPL | + | 10-25 | 0 | 25-50 | >75 |
| 9 | + | DLCL | IBPL | + | 0 | 0 | 0 | 25-50 |
| 10 | + | DLCL | IBPL | + | 10-25 | 0 | 10-25 | >75 |
| 11 | + | DLCL | IBPL | + | 0 | 0 | 0 | 10-25 |
| 12 | + | DLCL | IBPL | + | 50-75 | 0 | 50-75 | >75 |
| 13 | + | DLCL | IBPL | + | 10-25 | 0 | 10-25 | >75 |
| 14 | + | DLCL | IBPL | + | 10-25 | 0 | 25-50 | >75 |
| 15 | + | DLCL | LNCCL/IBPL | + | 25-50 | 25-50 | 25-50 | >75 |
| 16 | + | DLCL | LNCCL/IBPL | + | 25-50 | 10-25 | 10-25 | >75 |
| 27 | − | DLCL | LNCCL | − | 0 | 25-50 | 0 | >75 |
| 28 | − | DLCL | LNCCL | − | 0 | 10-25 | 0 | 0 |
| 29 | − | DLCL | LNCCL | − | 0 | 10-25 | 0 | >75 |
| 30 | − | DLCL | LNCCL | − | 0 | 50-75 | 0 | >75 |
| 31 | − | DLCL | LNCCL | − | 0 | >75 | 0 | >75 |
| 32 | − | DLCL | LNCCL | − | 0 | 50-75 | 50-75 | >75 |
| 33 | − | DLCL | LNCCL | − | 0 | 10-25 | 0 | >75 |
| 34 | − | DLCL | LNCCL | − | 0 | 10-25 | 0 | 25-50 |
| 35 | − | DLCL | LNCCL | − | 0 | 50-75 | 0 | >75 |
| 36 | − | DLCL | LNCCL | − | 0 | 10-25 | 0 | >75 |
| 37 | − | DLCL | LNCCL | − | 0 | 50-75 | 10-25 | >75 |
| 38 | − | DLCL | LNCCL | − | 0 | 25-50 | 0 | >75 |
| 39 | − | DLCL | LNCCL | − | 0 | 25-50 | 0 | >75 |
| 40 | − | DLCL | LNCCL | − | 0 | 50-75 | 0 | 50-75 |
| Case . | HIV . | Diagnosis . | EBV* . | Immunohistochemistry . | ||||
|---|---|---|---|---|---|---|---|---|
| REAL . | WF . | LMP-1 (%) . | BCL-6 (%) . | BCL-2 (%) . | hMSH2 (%) . | |||
| 1 | + | DLCL | LNCCL | + | 0 | 50-75 | 0 | >75 |
| 2 | + | DLCL | LNCCL | + | 0 | 25-50 | 0 | >75 |
| 3 | + | DLCL | LNCCL | + | 0 | 50-75 | 0 | >75 |
| 4 | + | DLCL | LNCCL | + | 0 | 25-50 | 0 | 50-75 |
| 5 | + | DLCL | LNCCL | + | 0 | 50-75 | 0 | >75 |
| 6 | + | DLCL | LNCCL | + | 0 | 10-25 | 0 | 50-75 |
| 7 | + | DLCL | LNCCL | + | 0 | 10-25 | 0 | 10-25 |
| 8 | + | DLCL | IBPL | + | 10-25 | 0 | 25-50 | >75 |
| 9 | + | DLCL | IBPL | + | 0 | 0 | 0 | 25-50 |
| 10 | + | DLCL | IBPL | + | 10-25 | 0 | 10-25 | >75 |
| 11 | + | DLCL | IBPL | + | 0 | 0 | 0 | 10-25 |
| 12 | + | DLCL | IBPL | + | 50-75 | 0 | 50-75 | >75 |
| 13 | + | DLCL | IBPL | + | 10-25 | 0 | 10-25 | >75 |
| 14 | + | DLCL | IBPL | + | 10-25 | 0 | 25-50 | >75 |
| 15 | + | DLCL | LNCCL/IBPL | + | 25-50 | 25-50 | 25-50 | >75 |
| 16 | + | DLCL | LNCCL/IBPL | + | 25-50 | 10-25 | 10-25 | >75 |
| 27 | − | DLCL | LNCCL | − | 0 | 25-50 | 0 | >75 |
| 28 | − | DLCL | LNCCL | − | 0 | 10-25 | 0 | 0 |
| 29 | − | DLCL | LNCCL | − | 0 | 10-25 | 0 | >75 |
| 30 | − | DLCL | LNCCL | − | 0 | 50-75 | 0 | >75 |
| 31 | − | DLCL | LNCCL | − | 0 | >75 | 0 | >75 |
| 32 | − | DLCL | LNCCL | − | 0 | 50-75 | 50-75 | >75 |
| 33 | − | DLCL | LNCCL | − | 0 | 10-25 | 0 | >75 |
| 34 | − | DLCL | LNCCL | − | 0 | 10-25 | 0 | 25-50 |
| 35 | − | DLCL | LNCCL | − | 0 | 50-75 | 0 | >75 |
| 36 | − | DLCL | LNCCL | − | 0 | 10-25 | 0 | >75 |
| 37 | − | DLCL | LNCCL | − | 0 | 50-75 | 10-25 | >75 |
| 38 | − | DLCL | LNCCL | − | 0 | 25-50 | 0 | >75 |
| 39 | − | DLCL | LNCCL | − | 0 | 25-50 | 0 | >75 |
| 40 | − | DLCL | LNCCL | − | 0 | 50-75 | 0 | 50-75 |
Abbreviations: REAL, Revised European-American Lymphoma classification; WF, Working Formulation.
EBV status as defined by EBER ISH studies.